Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5695578 | Gynecologic Oncology | 2017 | 10 Pages |
Abstract
There remains inadequate evidence to identify an optimal treatment for LAVC. However, there is sufficient evidence to support a trial of anovulvectomy versus chemoradiation. Discussions and consensus would be needed to determine trial criteria including the primary outcome measure. Neoadjuvant chemotherapy or radiotherapy alone may be best reserved for the palliative setting or metastatic disease.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Rachel Louise O'Donnell, Leen Verleye, Nithya Ratnavelu, Khadra Galaal, Ann Fisher, Raj Naik,